Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Recruiting 2Not yet recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 10Lymphoma, Mantle-Cell 6Lymphoma, B-Cell 6Lymphoma, Non-Hodgkin 5Waldenstrom Macroglobulinemia 3Leukemia, B-Cell 3Hematologic Diseases 3Recurrence 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Lymphoma, Follicular 1Leukemia, Lymphoid 1Leukemia 1Hematologic Neoplasms 1Chromosome 17 deletion 1

Interventions

Cyclophosphamide 5ibrutinib 4fludarabine 4pirtobrutinib 3obinutuzumab 3acalabrutinib 3fludarabine phosphate 2Rituximab 2Mesna 2venetoclax 1ricolinostat 1idelalisib 1Whole-Body Irradiation 1Vincristine 1Tacrolimus 1Stem Cell Transplantation 1Prednisone 1Peripheral Blood Stem Cell Transplantation 1Patient Reported Outcome Measures 1Mycophenolic Acid 1Melphalan 1Leukapheresis 1Doxorubicin 1Diet 1Busulfan 1Bone Marrow Transplantation 1ARQ531 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Leukemia, B-Cell × pirtobrutinib × 90 days × Clear all
NCT07624799 2026-06-03

PACIFIC

French Innovative Leukemia Organisation

Phase 2 Not yet recruiting
82 enrolled
LymphoidOther hematologic neoplasm

Leukemia, B-Cell

NCT07342478 2026-05-14

ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

Newave Pharmaceutical Inc

Phase 3 Recruiting
306 enrolled
LymphoidOther hematologic neoplasm

Chromosome 17 deletion, Recurrence, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT05254743 2026-04-20

BRUIN-CLL-314

Eli Lilly and Company

Phase 3 Recruiting
662 enrolled
LymphoidOther hematologic neoplasm

Hematologic Diseases, Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡